Blockade of TRAIL pathway ameliorates HBV-induced hepatocyte apoptosis in an acute hepatitis model.
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) may play important roles during hepatitis B virus (HBV) infection. In this study, we used a recombinant human soluble death receptor 5 (sDR5) to explore its effect in a mouse model of HBV-induced acute hepatitis. By measuring blood transaminase activity and hepatocyte apoptosis, we found that sDR5 could alleviate liver damage by blocking TRAIL-induced apoptosis of HBV-transfected hepatocytes. sDR5 injection at 16 mg/kg 24h before HBV transfection was the most effective. Additionally, we showed that sDR5 was equally effective in protecting liver injury as the Stronger Neo-Minophagen C (SNMC), a commonly used drug for patients with liver diseases. Thus, sDR5 represents a potential novel therapeutic drug for patients with fulminant hepatitis.
Liu
Yu-Gang
YG
Institute of Immunology, Shandong University School of Medicine, 44# Wenhua Xi Road, Jinan 250012, PR China.
Liu
Su-Xia
SX
Liang
Xiao-Hong
XH
Zhang
Qiu
Q
Gao
Li-Fen
LF
Han
Li-Hui
LH
Cao
Ying-Lin
YL
Hou
Nan
N
Du
Juan
J
Sun
Wen-Sheng
WS
D000208:Acute Disease; D000818:Animals; D017209:Apoptosis / Q000187:drug effects*; D004195:Disease Models, Animal; D006509:Hepatitis B / Q000378:metabolism* / Q000473:pathology* / Q000517:prevention & control; D006801:Humans; D007274:Injections, Intraperitoneal; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D053220:Receptors, TNF-Related Apoptosis-Inducing Ligand / Q000008:administration & dosage* / Q000737:chemistry / Q000235:genetics; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000737:chemistry; D015398:Signal Transduction / Q000187:drug effects*; D012995:Solubility; D053221:TNF-Related Apoptosis-Inducing Ligand / Q000378:metabolism*; D016896:Treatment Outcome
D053220:Receptors, TNF-Related Apoptosis-Inducing Ligand; D011994:Recombinant Proteins; D053221:TNF-Related Apoptosis-Inducing Ligand